Advertisement

Journal of Gastrointestinal Surgery

, Volume 19, Issue 2, pp 258–265 | Cite as

Current Recommendations for Surveillance and Surgery of Intraductal Papillary Mucinous Neoplasms May Overlook Some Patients with Cancer

  • Andrew H. Nguyen
  • Paul A. Toste
  • James J. Farrell
  • Barbara M. Clerkin
  • Jennifer Williams
  • V. Raman Muthusamy
  • Rabindra R. Watson
  • James S. Tomlinson
  • O. Joe Hines
  • Howard A. Reber
  • Timothy R. Donahue
Original Article

Abstract

Background

The 2012 Sendai Criteria recommend that patients with 3 cm or larger branch duct intraductal papillary mucinous neoplasms (BD-IPMN) without any additional “worrisome features” or “high-risk stigmata” may undergo close observation. Furthermore, endoscopic ultrasound (EUS) is not recommended for BD-IPMN <2 cm. These changes have generated concern among physicians treating patients with pancreatic diseases. The purposes of this study were to (i) apply the new Sendai guidelines to our institution’s surgically resected BD-IPMN and (ii) reevaluate cyst size cutoffs in identifying patients with lesions harboring high-grade dysplasia or invasive cancer.

Methods

We retrospectively reviewed 150 patients at a university medical center with preoperatively diagnosed and pathologically confirmed IPMNs. Sixty-six patients had BD-IPMN. Pathologic grade was dichotomized into low-grade (low or intermediate grade dysplasia) or high-grade/invasive (high-grade dysplasia or invasive cancers). Fisher’s exact test, chi-square test, student’s t test, linear regression, and receiver operating characteristic (ROC) analyses were performed.

Results

The median BD-IPMN size on imaging was 2.4 cm (interquartile range 1.5–3.0). Fifty-one (77 %) low-grade and 15 (23 %) high-grade/invasive BD-IPMN were identified. ROC analysis demonstrated that cyst size on preoperative imaging is a reasonable predictor of grade with an area under the curve of 0.691. Two-thirds of high-grade/invasive BD-IPMN were <3 cm (n = 10). Compared to a cutoff of 3, 2 cm was associated with higher sensitivity (73.3 vs. 33.3 %) and negative predictive value (83.3 vs. 80 %, NPV) for high-grade/invasive BD-IPMN. Mural nodules on endoscopic ultrasound (EUS) or atypical cells on endoscopic ultrasound-fine needle aspiration (EUS-FNA) were identified in all cysts <2 and only 50 % of those <3 cm. Forty percent of cysts >3 cm were removed based on size alone.

Discussion/Conclusions

Our results suggest that “larger” size on noninvasive imaging can indicate high-grade/invasive cysts, and EUS-FNA may help identify “smaller” cysts with high-grade/invasive pathology.

Keywords

Intraductal papillary mucinous neoplasm Branch duct intraductal papillary mucinous neoplasm Sendai criteria Pancreas 

Abbreviations

IPMN

Intraductal papillary mucinous neoplasms

BD-IPMN

Branch duct intraductal papillary mucinous neoplasms

MD-IPMN

Main duct intraductal papillary mucinous neoplasms

HRS

High-risk stigmata

WF

Worrisome features

ROC

Receiver operating characteristic

NPV

Negative predictive value

EUS

Endoscopic ultrasound

FNA

Fine needle aspiration

IQR

Interquartile range

AUC

Area under the curve

Notes

Funding/Support

Dr. Nguyen was supported by a T32 Training Award from the National Institute of Health (NIH T32DK07180-39) and the Gerald S. Levey Surgical Research Award.

References

  1. 1.
    Klibansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clinical Gastroenterology and Hepatology 2012;10(5):555–8.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Annals of Surgery 2004;239(6):788–97; discussion 97–9.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Lafemina J, Katabi N, Klimstra D, Correa-Gallego C, Gaujoux S, Kingham TP, et al. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. Annals of Surgical Oncology 2013;20(2):440–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Biankin AV, Kench JG, Biankin SA, Lee CS, Morey AL, Dijkman FP, et al. Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. The American Journal of Surgical Pathology 2004;28(9):1184–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Bassi C, Sarr MG, Lillemoe KD, Reber HA. Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. Journal of Gastrointestinal Surgery 2008;12(4):645–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Waters JA, Schmidt CM, Pinchot JW, White PB, Cummings OW, Pitt HA, et al. CT vs MRCP: optimal classification of IPMN type and extent. Journal of Gastrointestinal Surgery 2008;12(1):101–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK. MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. American Journal of Roentgenology 2006;186(3):687–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Nakagawa A, Yamaguchi T, Ohtsuka M, Ishihara T, Sudo K, Nakamura K, et al. Usefulness of multidetector computed tomography for detecting protruding lesions in intraductal papillary mucinous neoplasm of the pancreas in comparison with single-detector computed tomography and endoscopic ultrasonography. Pancreas 2009;38(2):131–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Gupta R, Mortele KJ, Tatli S, Girshman J, Glickman JN, Levy AD, et al. Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes. American Journal of Roentgenology 2008;191(5):1458–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 2014;46(1):22–9.PubMedGoogle Scholar
  11. 11.
    Pais SA, Attasaranya S, Leblanc JK, Sherman S, Schmidt CM, DeWitt J. Role of endoscopic ultrasound in the diagnosis of intraductal papillary mucinous neoplasms: correlation with surgical histopathology. Clinical Gastroenterology and Hepatology 2007;5(4):489–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Emerson RE, Randolph ML, Cramer HM. Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of intraductal papillary mucinous neoplasm of the pancreas is highly predictive of pancreatic neoplasia. Diagnostic Cytopathology 2006;34(7):457–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Ohno E, Hirooka Y, Itoh A, Ishigami M, Katano Y, Ohmiya N, et al. Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Annals of Surgery 2009;249(4):628–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Milchgrub S, Campuzano M, Casillas J, Albores-Saavedra J. Intraductal carcinoma of the pancreas. Cancer 1992;69(3):651–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Rickaert F, Cremer M, Deviere J, Tavares L, Lambilliotte JP, Schroder S, et al. Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology 1991;101(2):512–9.Google Scholar
  16. 16.
    Loftus EV, Jr., Olivares-Pakzad BA, Batts KP, Adkins MC, Stephens DH, Sarr MG, et al. Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology 1996;110(6):1909–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Jang JY, Kim SW, Ahn YJ, Yoon YS, Choi MG, Lee KU, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Annals of Surgical Oncology 2005;12(2):124–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Sugiyama M, Atomi Y. Intraductal papillary mucinous tumors of the pancreas: imaging studies and treatment strategies. Annals of Surgery 1998;228(5):685–91.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Allen PJ, Jaques DP, D’Angelica M, Bowne WB, Conlon KC, Brennan MF. Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients. Journal of Gastrointestinal Surgery 2003;7(8):970–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6(1–2):17–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Tang RS, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clinical Gastroenterology and Hepatology 2008;6(7):815–9; quiz 719.PubMedCrossRefGoogle Scholar
  22. 22.
    Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12(3):183–97.PubMedCrossRefGoogle Scholar
  23. 23.
    Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Annals of Surgery 2004;239(5):678–85; discussion 85–7.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Suzuki Y, Atomi Y, Sugiyama M, Isaji S, Inui K, Kimura W, et al. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 2004;28(3):241–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Crippa S, Partelli S, Falconi M. Extent of surgical resections for intraductal papillary mucinous neoplasms. World journal of gastrointestinal surgery 2010;2(10):347–51.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Kanno A, Satoh K, Hirota M, Hamada S, Umino J, Itoh H, et al. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. Journal of Gastroenterology 2010;45(9):952–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Moriya T, Hashimoto Y, Traverso LW. The duration of symptoms predicts the presence of malignancy in 210 resected cases of pancreatic intraductal papillary mucinous neoplasms. Journal of Gastrointestinal Surgery 2011;15(5):762–70; discussion 70–1.PubMedCrossRefGoogle Scholar
  28. 28.
    Tanaka M. Controversies in the management of pancreatic IPMN. Nature Reviews Gastroenterology & Hepatology 2011;8(1):56–60.CrossRefGoogle Scholar
  29. 29.
    Nagai K, Doi R, Kida A, Kami K, Kawaguchi Y, Ito T, et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World Journal of Surgery 2008;32(2):271–8; discussion 9–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Yang AD, Melstrom LG, Bentrem DJ, Ujiki MB, Wayne JD, Strouch M, et al. Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery 2007;142(4):529–34; discussion 34–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Annals of Surgery 2007;246(4):644–51; discussion 51–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Annals of Surgery 2012;256(2):313–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Jang JY, Kim SW, Lee SE, Yang SH, Lee KU, Lee YJ, et al. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Annals of Surgical Oncology 2008;15(1):199–205.PubMedCrossRefGoogle Scholar
  34. 34.
    Ohashi K, Murakami Y, Maruyama M. Four cases of mucin-producing cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endoscopy 1982(20):348–51.Google Scholar
  35. 35.
    Zhong N, Zhang L, Takahashi N, Shalmiyev V, Canto MI, Clain JE, et al. Histologic and imaging features of mural nodules in mucinous pancreatic cysts. Clinical Gastroenterology and Hepatology 2012;10(2):192–8, 8 e1-2.PubMedCrossRefGoogle Scholar
  36. 36.
    Hirano S, Kondo S, Tanaka E, Shichinohe T, Suzuki O, Shimizu M, et al. Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas. Hepatogastroenterology 2009;56(90):515–8.PubMedGoogle Scholar
  37. 37.
    Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, Ferrone CR, Sahani D, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Annals of Surgery 2013;258(3):466–75.PubMedCrossRefGoogle Scholar
  38. 38.
    Traverso LW, Moriya T, Hashimoto Y. Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history. Current Gastroenterology Reports 2012;14(2):106–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee JH, Lee KT, Park J, Bae SY, Lee KH, Lee JK, et al. Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms. World Journal of Gastroenterology 2010;16(42):5353–8.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Lubezky N, Ben-Haim M, Nakache R, Lahat G, Blachar A, Brazowski E, et al. Clinical presentation can predict disease course in patients with intraductal papillary mucinous neoplasm of the pancreas. World Journal of Surgery 2010;34(1):126–32.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2014

Authors and Affiliations

  • Andrew H. Nguyen
    • 1
  • Paul A. Toste
    • 1
  • James J. Farrell
    • 2
  • Barbara M. Clerkin
    • 1
  • Jennifer Williams
    • 3
  • V. Raman Muthusamy
    • 4
  • Rabindra R. Watson
    • 4
  • James S. Tomlinson
    • 1
  • O. Joe Hines
    • 1
  • Howard A. Reber
    • 1
  • Timothy R. Donahue
    • 1
  1. 1.Department of SurgeryDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Yale Center for Pancreatic DiseaseYale University School of MedicineNew HavenUSA
  3. 3.Department of SurgeryHarbor-UCLA Medical CenterTorranceUSA
  4. 4.UCLA Division of Digestive DiseasesDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations